<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="84386"><DrugName>RG-6042</DrugName><DrugSynonyms><Name><Value>antisense oligonucleotides (systemic, Huntington's disease), Isis / Roche</Value></Name><Name><Value>ISIS-HTTRx</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>ISIS-443139</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>IONIS-HTTRx</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>RG-6042</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>RO-7234292</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HTT antisense oligonucleotide therapy (Huntington's disease), Roche</Value></Name><Name><Value>HTT ASO, Roche</Value></Name></DrugSynonyms><CompanyOriginator id="17269">Ionis Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company id="19446">Roche Holding AG</Company><Company id="15414">Chugai Pharmaceutical Co Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="17269">Ionis Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="15414" type="Company"><TargetEntity id="4295876884" type="organizationId">Chugai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="17269" type="Company"><TargetEntity id="4295906873" type="organizationId">Ionis Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="19446" type="Company"><TargetEntity id="4295890594" type="organizationId">Roche Holding AG</TargetEntity></SourceEntity><SourceEntity id="170" type="ciIndication"><TargetEntity id="G10" type="ICD10"/><TargetEntity id="10020469" type="MEDDRA"/><TargetEntity id="D006816" type="MeSH"/><TargetEntity id="399" type="ORPHANET"/><TargetEntity id="-682751376" type="omicsDisease"/><TargetEntity id="126" type="siCondition"/></SourceEntity><SourceEntity id="15971" type="Action"><TargetEntity id="3119" type="Mechanism">HD (HTT) Expression Inhibitors</TargetEntity><TargetEntity id="4854" type="Mechanism">HD (HTT) (Mutant) Expression Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="10">PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="170">Huntingtons chorea</Indication></IndicationsPrimary><ActionsPrimary><Action id="15971">HTT gene inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="7294">Antisense oligonucleotide inhibitor</Action><Action id="1615">Neuroprotectant</Action></ActionsSecondary><Technologies><Technology id="569">Oligonucleotide antisense</Technology><Technology id="654">Intrathecal formulation</Technology><Technology id="94">RNA antisense</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2019-07-03T07:57:30.000Z</LastModificationDate><ChangeDateLast>2019-07-03T00:00:00.000Z</ChangeDateLast><AddedDate>2013-04-09T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="17269" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="19446" linkType="Company"&gt;Roche&lt;/ulink&gt; and &lt;ulink linkID="15414" linkType="Company"&gt;Chugai&lt;/ulink&gt;, under license from &lt;ulink linkID="17269" linkType="Company"&gt;Ionis Pharmaceuticals&lt;/ulink&gt; (formerly Isis Pharmaceuticals), are developing RG-6042 (HTT-ASO; IONIS-HTTRx; RO-7234292; ISIS-HTTRx; ISIS-443139), an antisense oligonucleotide (ASO) that silences huntingtin (HTT) mRNA and blocks all forms of the huntingtin protein, using Isis' ASO technology, for the potential intrathecal treatment of Huntington's disease (HD) [&lt;ulink linkID="1990699" linkType="Reference"&gt;1990699&lt;/ulink&gt;], [&lt;ulink linkID="1992162" linkType="Reference"&gt;1992162&lt;/ulink&gt;], [&lt;ulink linkID="2009686" linkType="Reference"&gt;2009686&lt;/ulink&gt;], [&lt;ulink linkID="2062833" linkType="Reference"&gt;2062833&lt;/ulink&gt;]. In January 2019, a phase III trial was initiated in patients with manifest Huntington's disease (HD). At that time, the trial was expected to complete in August 2022 [&lt;ulink linkID="2101824" linkType="Reference"&gt;2101824&lt;/ulink&gt;]. In March 2019, Chugai started development in Japan as part of the multinational phase III trial [&lt;ulink linkID="2144705" linkType="Reference"&gt;2144705&lt;/ulink&gt;], [&lt;ulink linkID="2145151" linkType="Reference"&gt;2145151&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Ionis was previously planning to combine its ASOs with Roche's 'brain shuttle'  program to enhance ASO   brain penetration  via systemic administration  [&lt;ulink linkID="1400846" linkType="Reference"&gt;1400846&lt;/ulink&gt;], [&lt;ulink linkID="1553514" linkType="Reference"&gt;1553514&lt;/ulink&gt;], [&lt;ulink linkID="1722606" linkType="Reference"&gt;1722606&lt;/ulink&gt;], [&lt;ulink linkID="1724795" linkType="Reference"&gt;1724795&lt;/ulink&gt;], [&lt;ulink linkID="1990699" linkType="Reference"&gt;1990699&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In January 2019, filings for RG-6042 were expected in 2021 or later [&lt;ulink linkID="2115523" linkType="Reference"&gt;2115523&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2015, the FDA granted Orphan Drug status to RG-6042 for the treatment of HD [&lt;ulink linkID="1724795" linkType="Reference"&gt;1724795&lt;/ulink&gt;], [&lt;ulink linkID="1725475" linkType="Reference"&gt;1725475&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In January 2019, filings for RG-6042 were expected in 2021 or later [&lt;ulink linkID="2115523" linkType="Reference"&gt;2115523&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2018, the EMA granted PRIority MEdicines (PRIME) designation to RG-6042 for the treatment of Huntington's disease [&lt;ulink linkID="2059620" linkType="Reference"&gt;2059620&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2015,  the EMA's COMP adopted a positive opinion recommending chimeric 2'-O-(2-methoxyethyl) modified oligonucleotide targeted to huntingtin RNA, presumed to be RG-6042,  for Orphan Drug designation for the treatment of HD [&lt;ulink linkID="1638683" linkType="Reference"&gt;1638683&lt;/ulink&gt;]; in March 2015, Orphan designation was granted [&lt;ulink linkID="1646151" linkType="Reference"&gt;1646151&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In July 2016, phase III trials were planned to begin in the next one to three years [&lt;ulink linkID="1781357" linkType="Reference"&gt;1781357&lt;/ulink&gt;]. In March 2018,  a pivotal trial to determine the clinical efficacy and safety of RG-6042 was planned [&lt;ulink linkID="2009686" linkType="Reference"&gt;2009686&lt;/ulink&gt;]. In May 2018, phase II/III development was expected to begin in 2018 [&lt;ulink linkID="2046831" linkType="Reference"&gt;2046831&lt;/ulink&gt;]. In August 2018, a phase III study to evaluate safety profile in larger patient population was planned to be initiated as soon as possible [&lt;ulink linkID="2059986" linkType="Reference"&gt;2059986&lt;/ulink&gt;]. In December 2018, a randomized, multicenter, double-blind, placebo-controlled, parallel assignment, phase III study (&lt;ulink linkID="362282" linkType="Protocol"&gt;NCT03761849&lt;/ulink&gt;; BN40423; Generation HD1) to assess efficacy and safety of intrathecally administered drug in patients (expected n = 660) with manifest Huntington's disease was to be initiated later that month [&lt;ulink linkID="2101824" linkType="Reference"&gt;2101824&lt;/ulink&gt;], [&lt;ulink linkID="2115523" linkType="Reference"&gt;2115523&lt;/ulink&gt;]. The primary endpoint was change from baseline in the composite unified Huntington's disease rating scale (cUHDRS) and TFC Score over 101 weeks. At that time, the trial was expected to complete in August 2022 [&lt;ulink linkID="2101824" linkType="Reference"&gt;2101824&lt;/ulink&gt;]. In January 2019, the trial was initiated in the US, Canada, Spain and the UK [&lt;ulink linkID="2101824" linkType="Reference"&gt;2101824&lt;/ulink&gt;], [&lt;ulink linkID="2114280" linkType="Reference"&gt;2114280&lt;/ulink&gt;]. In March 2019, Chugai started development in Japan as part of the multinational phase III trial [&lt;ulink linkID="2144705" linkType="Reference"&gt;2144705&lt;/ulink&gt;], [&lt;ulink linkID="2145151" linkType="Reference"&gt;2145151&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In August 2017, an OLE study was to be initiated in the second half of 2017 [&lt;ulink linkID="1951437" linkType="Reference"&gt;1951437&lt;/ulink&gt;]. In November 2017, the randomized, open-label, phase II OLE trial (&lt;ulink linkID="319505" linkType="Protocol"&gt;NCT03342053&lt;/ulink&gt;; BN406970) was initiated to evaluate longer-term safety, tolerability, pharmacokinetics, and pharmacodynamics of RG-6042 in HD patients (n = 46) in Canada, Germany and the UK who participated in the phase I/II study (&lt;ulink linkID="236923" linkType="Protocol"&gt;NCT02519036&lt;/ulink&gt;).The primary endpoint was incidence of treatment-emergent adverse events. In January 2019, the trial was no longer recruiting and was expected to complete in October 2019 [&lt;ulink linkID="2115965" linkType="Reference"&gt;2115965&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2015, a randomized, placebo-controlled, dose escalation, safety phase I/IIa trial was initiated in patients with HD. In the study, RG-6042 would be administered intrathecally as an injection directly into the cerebral spinal fluid [&lt;ulink linkID="1679021" linkType="Reference"&gt;1679021&lt;/ulink&gt;].In August 2015, the phase I/II randomized, double-blind, placebo-controlled study (&lt;ulink linkID="236923" linkType="Protocol"&gt;NCT02519036&lt;/ulink&gt;; ISIS 443139-CS1) to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered RG-6042 was expected to be initiated in patients (expected n = 36) with early manifest HD in Canada, Germany and the UK. At that time, the study was expected to complete in September 2017. Later that month recruitment was initiated in Canada and in March 2017, recruitment was underway in the UK and Germany[&lt;ulink linkID="1685380" linkType="Reference"&gt;1685380&lt;/ulink&gt;]. In June 2017, patient enrollment was completed. Dosing in the patient cohort continued. Top-line results from the trial were expected around year-end 2017 or early 2018. At that time,  patients who had completed the study would be eligible to participate in an open-label extension (OLE) study that the company was planning to initiate in the next several months [&lt;ulink linkID="1939904" linkType="Reference"&gt;1939904&lt;/ulink&gt;], [&lt;ulink linkID="1951437" linkType="Reference"&gt;1951437&lt;/ulink&gt;]. In December 2017, data from the trial were reported. Data demonstrated that dose-dependent reductions of mHTT were observed in participants treated with RG-6042. Also, the safety and tolerability profile of RG-6042 observed in the study supported continued development. At that time, results were expected to be presented at medical conferences in the first half of 2018 and planned to submit the study results for publication in a peer-reviewed medical journal [&lt;ulink linkID="1990699" linkType="Reference"&gt;1990699&lt;/ulink&gt;]. In March 2018, positive top-line data from the study (n = 46) were presented at the  13th Annual CHDI HD conference.  Data demonstrated a significant dose-dependent reductions in mHTT in CSF, with approximately 60% and 40% reductions in patients dosed with 90 mg and 120 mg (p&amp;lt;0.01). Further more, the levels of mHTT were continuing to decline and expected a maximum reduction in six months after first dose. The drug was safe and well-tolerated. A reduction of 40% to 60%  in CSF of rodents and non-human primates, corresponds to an estimated 55% to 85% reduction in mHTT in the cortex and 20% to 50% in the caudate regions of the brain in humans. At that time, OLE study was ongoing [&lt;ulink linkID="2009686" linkType="Reference"&gt;2009686&lt;/ulink&gt;]. In April 2018, further clinical data were presented at the 70th AAN Annual Meeting in Los Angeles, CA. RG-6042 was well-tolerated at all doses tested with no adverse trends in laboratory parameters. Majority of adverse events were mild in severity and unrelated to study drug [&lt;ulink linkID="2026165" linkType="Reference"&gt;2026165&lt;/ulink&gt;],[&lt;ulink linkID="2027210" linkType="Reference"&gt;2027210&lt;/ulink&gt;]. In May 2019, data from the trial were published.  The drug lowered levels of the mutant huntingtin protein  [&lt;ulink linkID="2148443" linkType="Reference"&gt;2148443&lt;/ulink&gt;], [&lt;ulink linkID="2149020" linkType="Reference"&gt;2149020&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In July 2019, an IND application was filed in China [&lt;ulink linkID="2169164" linkType="Reference"&gt;2169164&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2016, preclinical data were presented at the 46th SFN Annual Meeting in San Diego, CA. In non-human primates (NHP), huntingtin antisense oligonucleotides (intrathecal, two dose levels) suppressed the huntingtin mRNA throughout the CNS of NHPs, including cortical regions, thalamus, caudate and all key regions of Huntington's disease. The suppression of mRNA was sustained and was present 8-weeks post dosing [&lt;ulink linkID="1871228" linkType="Reference"&gt;1871228&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016  preclinical data were presented at were presented at the 68th AAN Annual Meeting in Vancouver, Canada. In non human primates, RG-6042 was well-tolerated following repeated intrathecal injections over a 3-month period   [&lt;ulink linkID="1755141" linkType="Reference"&gt;1755141&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2015,  preclinical data were reported. Data demonstrated that the drug had produced a significant reduction in HTT mRNA and protein, delayed disease progression and prolonged the survival in a mouse model of HD [&lt;ulink linkID="1644153" linkType="Reference"&gt;1644153&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2015, the program was listed as being in preclinical development on Isis's pipeline [&lt;ulink linkID="1633344" linkType="Reference"&gt;1633344&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2013, preclinical data were presented at the 43rd SFN Meeting in San Diego, CA. Lead allele-specific antisense oligonucleotide  dose-dependently decreased mutant huntingtin protein but not wild-type huntingtin protein and this compound was safe and well tolerated [&lt;ulink linkID="1494731" linkType="Reference"&gt;1494731&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2013, Isis had identified a lead drug candidate [&lt;ulink linkID="1400846" linkType="Reference"&gt;1400846&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate>2019-01-23T00:00:00.000Z</StatusDate><Source id="2101824" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate>2019-03-31T00:00:00.000Z</StatusDate><Source id="2144705" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate>2019-01-17T00:00:00.000Z</StatusDate><Source id="2114280" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate>2019-01-17T00:00:00.000Z</StatusDate><Source id="2114280" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate>2019-01-23T00:00:00.000Z</StatusDate><Source id="2101824" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate>2019-07-03T00:00:00.000Z</StatusDate><Source id="2169164" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17269">Ionis Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate>2017-12-11T00:00:00.000Z</StatusDate><Source id="1990699" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17269">Ionis Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate>2017-12-11T00:00:00.000Z</StatusDate><Source id="1990699" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17269">Ionis Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate>2017-12-11T00:00:00.000Z</StatusDate><Source id="1990699" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17269">Ionis Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate>2013-04-08T00:00:00.000Z</StatusDate><Source id="1400846" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17269">Ionis Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate>2015-02-10T00:00:00.000Z</StatusDate><Source id="1638683" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17269">Ionis Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate>2015-08-01T00:00:00.000Z</StatusDate><Source id="1685380" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17269">Ionis Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate>2017-03-08T00:00:00.000Z</StatusDate><Source id="1679021" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17269">Ionis Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate>2015-08-12T00:00:00.000Z</StatusDate><Source id="1685380" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate>2017-12-11T00:00:00.000Z</StatusDate><Source id="1990699" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate>2017-12-11T00:00:00.000Z</StatusDate><Source id="1990699" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate>2017-12-11T00:00:00.000Z</StatusDate><Source id="1990699" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17269">Ionis Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="170">Huntingtons chorea</Indication><AwardedIndication>Treatment of Huntington's disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-12-29T00:00:00.000Z</MileStoneDate><Source id="1725475" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17269">Ionis Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="170">Huntingtons chorea</Indication><AwardedIndication>Treatment of Huntington’s disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-03-19T00:00:00.000Z</MileStoneDate><Source id="1646151" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="17269">Ionis Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="170">Huntingtons chorea</Indication><AwardedIndication>Treatment of Huntington’s disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2015-02-12T00:00:00.000Z</MileStoneDate><Source id="1638683" type="PR"/></Row><Row><RegulatoryDesignation id="10">PRIME</RegulatoryDesignation><OwnerCompany id="17269">Ionis Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="170">Huntingtons chorea</Indication><AwardedIndication>Treatment of Huntington's disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-08-02T00:00:00.000Z</MileStoneDate><Source id="2059620" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="GTGT-04372"><Name>HTT gene</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1045019">Muscular Dystrophy Association</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17269">Ionis Pharmaceuticals Inc</Company><CountAsPrincipalActive>3</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>3</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="19446">Roche Holding AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20607">University of London</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21091">Ludwig Institute for Cancer Research</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="21864">University of Texas System</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="144706" title="Isis and Roche to develop antisense oligonucleotides for Huntington's disease       "/><Deal id="144710" title="Ludwig Institute and Isis Pharmaceuticals to collaborate on the development of antisense oligonucleotide for HD "/><Deal id="144711" title="University of Texas Southwestern and Isis Pharmaceuticals to collaborate on the development of antisense oligonucleotide for HD  "/><Deal id="244561" title="UCL to conduct trial for Ionis Pharmaceuticals' IONIS-HTTRx against HD"/><Deal id="254919" title="MDA to award funding to Ludwig Institute to detemine the suppression of stathmin-2 protein of RG-6042 in non-familial ALS "/></Deals><PatentFamilies><PatentFamily id="2717404" number="WO-2014059356" title="Selective antisense compounds and uses thereof"/><PatentFamily id="2781006" number="WO-2014121287" title="Selective antisense compounds and uses thereof"/><PatentFamily id="3063027" number="WO-2015168172" title="Linkage modified oligomeric compounds"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Centre Hospitalier Universitaire De Quebec" id="1019871"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ionis Pharmaceuticals Inc" id="17269"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Rochester" id="20669"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>